Accessibility as a conditioning factor in treatment for exudative age-related macular degeneration
- Autores
- Real, Juan Pablo; Luna, José Domingo; Urrets Zavalía, Julio Alberto; de Santis, Mariana Olga; Palma, Santiago Daniel; Granero, Gladys Ester
- Año de publicación
- 2013
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Purpose: Ranibizumab and bevacizumab coexist as the main therapeutic strategies for the treatment of neovascular age-related macular degeneration (NV-AMD). In Argentina, the access pathways to the drugs are different. Patients with different pathways and gatekeepers to access may experience different outcomes. The purpose of this work was to estimate the impact on therapeutic effects and visual outcome of the different accessibilities to NV-AMD treatment.
Methods: A retrospective analysis of the charts of 78 patients with previously untreated exudative AMD, who were treated with ranibizumab or bevacizumab between January 2009 and December 2011, was conducted. The main outcomes measured included time delay and change in mean best-corrected visual acuity (BCVA) between diagnosis and treatment and mean BCVA change at 1-year follow-ups.
Results: The delay between diagnosis and treatment and decrease in visual acuity over this time was significantly higher for patients treated with ranibizumab. At 1 year after the initiation of treatment, BCVA had a mean increase from baseline of 0.11 letters in the bevacizumab group with a mean of 4.71 injections, compared with a decrease of 8.87 letters with a mean of 2.98 injections in the ranibizumab group.
Conclusions: Access to treatment can be a key factor for success of therapy. Waiting times and availability of doses are crucial in the treatment of NV-AMD. Solving the problems related to delayed initiation of therapy and the difficulties in the maintenance phase are more important than define whether bevacizumab or ranibizumab is used.
Fil: Real, Juan Pablo. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Departamento de Farmacia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Luna, José Domingo. Fundación Ver; Argentina
Fil: Urrets Zavalía, Julio Alberto. Universidad Catolica de Córdoba. Facultad de Medicina. Clinica Universitaria Reina Fabiola; Argentina
Fil: de Santis, Mariana Olga. Universidad Nacional de Córdoba. Facultad de Ciencias Económicas; Argentina
Fil: Palma, Santiago Daniel. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Departamento de Farmacia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Granero, Gladys Ester. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Departamento de Farmacia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina - Materia
-
Bevacizumab
Cohort Studies
Health Services Accessibility
Macular Degeneration - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
.jpg)
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/25255
Ver los metadatos del registro completo
| id |
CONICETDig_fea51392d1533476d45a65d296729afa |
|---|---|
| oai_identifier_str |
oai:ri.conicet.gov.ar:11336/25255 |
| network_acronym_str |
CONICETDig |
| repository_id_str |
3498 |
| network_name_str |
CONICET Digital (CONICET) |
| spelling |
Accessibility as a conditioning factor in treatment for exudative age-related macular degenerationReal, Juan PabloLuna, José DomingoUrrets Zavalía, Julio Albertode Santis, Mariana OlgaPalma, Santiago DanielGranero, Gladys EsterBevacizumabCohort StudiesHealth Services AccessibilityMacular Degenerationhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Purpose: Ranibizumab and bevacizumab coexist as the main therapeutic strategies for the treatment of neovascular age-related macular degeneration (NV-AMD). In Argentina, the access pathways to the drugs are different. Patients with different pathways and gatekeepers to access may experience different outcomes. The purpose of this work was to estimate the impact on therapeutic effects and visual outcome of the different accessibilities to NV-AMD treatment.
Methods: A retrospective analysis of the charts of 78 patients with previously untreated exudative AMD, who were treated with ranibizumab or bevacizumab between January 2009 and December 2011, was conducted. The main outcomes measured included time delay and change in mean best-corrected visual acuity (BCVA) between diagnosis and treatment and mean BCVA change at 1-year follow-ups.
Results: The delay between diagnosis and treatment and decrease in visual acuity over this time was significantly higher for patients treated with ranibizumab. At 1 year after the initiation of treatment, BCVA had a mean increase from baseline of 0.11 letters in the bevacizumab group with a mean of 4.71 injections, compared with a decrease of 8.87 letters with a mean of 2.98 injections in the ranibizumab group.
Conclusions: Access to treatment can be a key factor for success of therapy. Waiting times and availability of doses are crucial in the treatment of NV-AMD. Solving the problems related to delayed initiation of therapy and the difficulties in the maintenance phase are more important than define whether bevacizumab or ranibizumab is used.Fil: Real, Juan Pablo. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Departamento de Farmacia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Luna, José Domingo. Fundación Ver; ArgentinaFil: Urrets Zavalía, Julio Alberto. Universidad Catolica de Córdoba. Facultad de Medicina. Clinica Universitaria Reina Fabiola; ArgentinaFil: de Santis, Mariana Olga. Universidad Nacional de Córdoba. Facultad de Ciencias Económicas; ArgentinaFil: Palma, Santiago Daniel. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Departamento de Farmacia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Granero, Gladys Ester. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Departamento de Farmacia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaWichtig Editore2013-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/25255Real, Juan Pablo; Luna, José Domingo; Urrets Zavalía, Julio Alberto; de Santis, Mariana Olga; Palma, Santiago Daniel; et al.; Accessibility as a conditioning factor in treatment for exudative age-related macular degeneration; Wichtig Editore; European Journal Of Ophthalmology; 23; 6; 5-2013; 857-8641120-6721CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.5301/ejo.5000299info:eu-repo/semantics/altIdentifier/url/http://www.eur-j-ophthalmol.com/article/accessibility-as-a-conditioning-factor-in-treatment-for-exudative-age-related-macular-degenerationinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:24:41Zoai:ri.conicet.gov.ar:11336/25255instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:24:41.44CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
| dc.title.none.fl_str_mv |
Accessibility as a conditioning factor in treatment for exudative age-related macular degeneration |
| title |
Accessibility as a conditioning factor in treatment for exudative age-related macular degeneration |
| spellingShingle |
Accessibility as a conditioning factor in treatment for exudative age-related macular degeneration Real, Juan Pablo Bevacizumab Cohort Studies Health Services Accessibility Macular Degeneration |
| title_short |
Accessibility as a conditioning factor in treatment for exudative age-related macular degeneration |
| title_full |
Accessibility as a conditioning factor in treatment for exudative age-related macular degeneration |
| title_fullStr |
Accessibility as a conditioning factor in treatment for exudative age-related macular degeneration |
| title_full_unstemmed |
Accessibility as a conditioning factor in treatment for exudative age-related macular degeneration |
| title_sort |
Accessibility as a conditioning factor in treatment for exudative age-related macular degeneration |
| dc.creator.none.fl_str_mv |
Real, Juan Pablo Luna, José Domingo Urrets Zavalía, Julio Alberto de Santis, Mariana Olga Palma, Santiago Daniel Granero, Gladys Ester |
| author |
Real, Juan Pablo |
| author_facet |
Real, Juan Pablo Luna, José Domingo Urrets Zavalía, Julio Alberto de Santis, Mariana Olga Palma, Santiago Daniel Granero, Gladys Ester |
| author_role |
author |
| author2 |
Luna, José Domingo Urrets Zavalía, Julio Alberto de Santis, Mariana Olga Palma, Santiago Daniel Granero, Gladys Ester |
| author2_role |
author author author author author |
| dc.subject.none.fl_str_mv |
Bevacizumab Cohort Studies Health Services Accessibility Macular Degeneration |
| topic |
Bevacizumab Cohort Studies Health Services Accessibility Macular Degeneration |
| purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.3 https://purl.org/becyt/ford/3 |
| dc.description.none.fl_txt_mv |
Purpose: Ranibizumab and bevacizumab coexist as the main therapeutic strategies for the treatment of neovascular age-related macular degeneration (NV-AMD). In Argentina, the access pathways to the drugs are different. Patients with different pathways and gatekeepers to access may experience different outcomes. The purpose of this work was to estimate the impact on therapeutic effects and visual outcome of the different accessibilities to NV-AMD treatment.
Methods: A retrospective analysis of the charts of 78 patients with previously untreated exudative AMD, who were treated with ranibizumab or bevacizumab between January 2009 and December 2011, was conducted. The main outcomes measured included time delay and change in mean best-corrected visual acuity (BCVA) between diagnosis and treatment and mean BCVA change at 1-year follow-ups.
Results: The delay between diagnosis and treatment and decrease in visual acuity over this time was significantly higher for patients treated with ranibizumab. At 1 year after the initiation of treatment, BCVA had a mean increase from baseline of 0.11 letters in the bevacizumab group with a mean of 4.71 injections, compared with a decrease of 8.87 letters with a mean of 2.98 injections in the ranibizumab group.
Conclusions: Access to treatment can be a key factor for success of therapy. Waiting times and availability of doses are crucial in the treatment of NV-AMD. Solving the problems related to delayed initiation of therapy and the difficulties in the maintenance phase are more important than define whether bevacizumab or ranibizumab is used. Fil: Real, Juan Pablo. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Departamento de Farmacia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Luna, José Domingo. Fundación Ver; Argentina Fil: Urrets Zavalía, Julio Alberto. Universidad Catolica de Córdoba. Facultad de Medicina. Clinica Universitaria Reina Fabiola; Argentina Fil: de Santis, Mariana Olga. Universidad Nacional de Córdoba. Facultad de Ciencias Económicas; Argentina Fil: Palma, Santiago Daniel. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Departamento de Farmacia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Granero, Gladys Ester. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Departamento de Farmacia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina |
| description |
Purpose: Ranibizumab and bevacizumab coexist as the main therapeutic strategies for the treatment of neovascular age-related macular degeneration (NV-AMD). In Argentina, the access pathways to the drugs are different. Patients with different pathways and gatekeepers to access may experience different outcomes. The purpose of this work was to estimate the impact on therapeutic effects and visual outcome of the different accessibilities to NV-AMD treatment.
Methods: A retrospective analysis of the charts of 78 patients with previously untreated exudative AMD, who were treated with ranibizumab or bevacizumab between January 2009 and December 2011, was conducted. The main outcomes measured included time delay and change in mean best-corrected visual acuity (BCVA) between diagnosis and treatment and mean BCVA change at 1-year follow-ups.
Results: The delay between diagnosis and treatment and decrease in visual acuity over this time was significantly higher for patients treated with ranibizumab. At 1 year after the initiation of treatment, BCVA had a mean increase from baseline of 0.11 letters in the bevacizumab group with a mean of 4.71 injections, compared with a decrease of 8.87 letters with a mean of 2.98 injections in the ranibizumab group.
Conclusions: Access to treatment can be a key factor for success of therapy. Waiting times and availability of doses are crucial in the treatment of NV-AMD. Solving the problems related to delayed initiation of therapy and the difficulties in the maintenance phase are more important than define whether bevacizumab or ranibizumab is used. |
| publishDate |
2013 |
| dc.date.none.fl_str_mv |
2013-05 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/25255 Real, Juan Pablo; Luna, José Domingo; Urrets Zavalía, Julio Alberto; de Santis, Mariana Olga; Palma, Santiago Daniel; et al.; Accessibility as a conditioning factor in treatment for exudative age-related macular degeneration; Wichtig Editore; European Journal Of Ophthalmology; 23; 6; 5-2013; 857-864 1120-6721 CONICET Digital CONICET |
| url |
http://hdl.handle.net/11336/25255 |
| identifier_str_mv |
Real, Juan Pablo; Luna, José Domingo; Urrets Zavalía, Julio Alberto; de Santis, Mariana Olga; Palma, Santiago Daniel; et al.; Accessibility as a conditioning factor in treatment for exudative age-related macular degeneration; Wichtig Editore; European Journal Of Ophthalmology; 23; 6; 5-2013; 857-864 1120-6721 CONICET Digital CONICET |
| dc.language.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.5301/ejo.5000299 info:eu-repo/semantics/altIdentifier/url/http://www.eur-j-ophthalmol.com/article/accessibility-as-a-conditioning-factor-in-treatment-for-exudative-age-related-macular-degeneration |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
| dc.format.none.fl_str_mv |
application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
Wichtig Editore |
| publisher.none.fl_str_mv |
Wichtig Editore |
| dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
| reponame_str |
CONICET Digital (CONICET) |
| collection |
CONICET Digital (CONICET) |
| instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
| _version_ |
1844614243853271040 |
| score |
13.070432 |